Sugi Predict

Sugi Predict / Targets / PIM2

PIM2

Serine/threonine-protein kinase pim-2 · Q9P1W9 · PIM2 on Sugi Atlas →

120,750 patent compounds predicted against PIM2, 66,051 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL319071 SCHEMBL319071 0.64 20/20
SCHEMBL327448 SCHEMBL327448 0.63 20/20
SCHEMBL319029 SCHEMBL319029 0.63 20/20
SCHEMBL319072 SCHEMBL319072 0.60 20/20
SCHEMBL319025 SCHEMBL319025 0.58 20/20
SCHEMBL319198 SCHEMBL319198 0.58 20/20
SCHEMBL319325 SCHEMBL319325 0.57 20/20
SCHEMBL319581 SCHEMBL319581 0.56 20/20
SCHEMBL319019 SCHEMBL319019 0.56 20/20
SCHEMBL319494 SCHEMBL319494 0.55 20/20
SCHEMBL319678 SCHEMBL319678 0.55 20/20
SCHEMBL318980 SCHEMBL318980 0.54 20/20
SCHEMBL319635 SCHEMBL319635 0.54 20/20
SCHEMBL319834 SCHEMBL319834 0.54 20/20
SCHEMBL319256 SCHEMBL319256 0.53 20/20
SCHEMBL319399 SCHEMBL319399 0.53 20/20
SCHEMBL319793 SCHEMBL319793 0.53 20/20
SCHEMBL320006 SCHEMBL320006 0.53 20/20
SCHEMBL325024 SCHEMBL325024 0.52 20/20
SCHEMBL325025 SCHEMBL325025 0.52 20/20

Clinical trials — most relevant to PIM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy PHASE3COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML PHASE2RECRUITING
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer PHASE2RECRUITING
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma PHASE2RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer PHASE2ENROLLING_BY_INVITATION
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects PHASE1COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects PHASE1COMPLETED
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) PHASE1COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function PHASE1COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Evaluation of Hypoxia in Primary Melanoma nanRECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PIM2 binder may also engage these)

ProteinNameSimilarity
B1WBU5 — 0.977 B1WBU5 →
P0C5K1 — 0.976 P0C5K1 →
Q95LJ0 — 0.972 Q95LJ0 →
PKN3 Serine/threonine-protein kinase N3 0.969 landscape →
SBK3 Uncharacterized serine/threonine-protein kinase SBK3 0.969 landscape →
Q9N0P9 — 0.968 Q9N0P9 →
P0C263 — 0.965 P0C263 →
Q8K045 — 0.965 Q8K045 →
P58750 — 0.965 P58750 →
O70444 — 0.964 O70444 →
PIM1 Serine/threonine-protein kinase pim-1 0.964 landscape →
P26794 — 0.963 P26794 →
P06803 — 0.962 P06803 →
P0C5K0 — 0.960 P0C5K0 →
Q4FZD7 — 0.960 Q4FZD7 →
Q62070 — 0.959 Q62070 →
P08923 — 0.958 P08923 →
PIM3 Serine/threonine-protein kinase pim-3 0.958 landscape →
PLK3 Serine/threonine-protein kinase PLK3 0.956 landscape →
Q60806 — 0.954 Q60806 →
Q9R011 — 0.954 Q9R011 →
P23049 — 0.953 P23049 →
A8VU90 — 0.953 A8VU90 →
Q28616 — 0.953 Q28616 →
Q49HH9 — 0.952 Q49HH9 →
Q99ML2 — 0.952 Q99ML2 →
Q643R3 — 0.952 Q643R3 →
AXL Tyrosine-protein kinase receptor UFO 0.951 landscape →
Q91ZT7 — 0.951 Q91ZT7 →
Q49KI5 — 0.951 Q49KI5 →